Literature DB >> 10210824

The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit.

.   

Abstract

The management and clinical course of patients with myasthenia gravis admitted to a neurological intensive therapy unit (ITU) over a 66 month period were reviewed. Twenty-seven patients were admitted in myasthenic crisis, eight of whom had multiple admissions. One patient had a cholinergic crisis and a further patient an acute myocardial infarction. A specific aetiological factor precipitating myasthenic crisis was identified in 19 instances: infection (8), reduction in medication (5), menstruation (4), and steroid administration (2). Thirteen patients with crisis had had a previous thymectomy, six with thymoma. Twenty-three out of 35 (66%) patients admitted in crisis required intubation; nine subsequently needed a tracheostomy. Twenty-nine patients received plasma exchange and seven intravenous immunoglobulin. Four patients in myasthenic crisis died in ITU [adult respiratory distress syndrome (1), disseminated intravascular coagulation and cytomegalovirus (CMV) pneumonitis (1), cardiac failure (1) and multiple organ failure (1)]. Appropriate management of myasthenia gravis requires the easy availability of specialised neuro-intensive care facilities. Copyright Rapid Science Ltd

Entities:  

Year:  1998        PMID: 10210824     DOI: 10.1046/j.1468-1331.1998.520137.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  13 in total

1.  Myasthenic crisis.

Authors:  Linda C Wendell; Joshua M Levine
Journal:  Neurohospitalist       Date:  2011-01

Review 2.  Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.

Authors:  Yoshihisa Kadota; Hirotoshi Horio; Takeshi Mori; Noriyoshi Sawabata; Taichiro Goto; Shin-ichi Yamashita; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-22

3.  Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001.

Authors:  J F Owe; A K Daltveit; N E Gilhus
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

4.  COVID-19 and Sepsis in an Atypical Case of Mixed Connective Tissue Disorder Presenting With a Myasthenic Crisis.

Authors:  Lav Kumar Shah; Biswas Pant; Nashruva Mony; Sumitanand Mishra; Januka Gaire; Sandesh Sharma
Journal:  Cureus       Date:  2022-09-12

5.  Myasthenia gravis treated in the neurology intensive care unit: a 14-year single-centre experience.

Authors:  Mirjana Zdraljevic; Stojan Peric; Marta Jeremic; Dragana Lavrnic; Ivana Basta; Ljiljana Hajdukovic; Dejana R Jovanovic; Ivana Berisavac
Journal:  Neurol Sci       Date:  2022-09-09       Impact factor: 3.830

6.  The effect of secular trends and specialist neurocritical care on mortality for patients with intracerebral haemorrhage, myasthenia gravis and Guillain-Barré syndrome admitted to critical care : an analysis of the Intensive Care National Audit & Research Centre (ICNARC) national United Kingdom database.

Authors:  Maxwell S Damian; Yoav Ben-Shlomo; Robin Howard; Tony Bellotti; David Harrison; Kathryn Griggs; Kathryn Rowan
Journal:  Intensive Care Med       Date:  2013-05-24       Impact factor: 17.440

Review 7.  Pain management in neurocritical care.

Authors:  Axel Petzold; Armand Girbes
Journal:  Neurocrit Care       Date:  2013-10       Impact factor: 3.210

8.  Outcome of therapeutic plasma exchange in Myasthenia gravis patients.

Authors:  Ashu Dogra; Kaushik Rana; Chirag Rathod; Sanjay Prakash
Journal:  J Family Med Prim Care       Date:  2020-12-31

Review 9.  Respiratory management of patients with neuromuscular disease: current perspectives.

Authors:  Gerald Pfeffer; Marcus Povitz
Journal:  Degener Neurol Neuromuscul Dis       Date:  2016-11-18

10.  Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: a 17-year experience.

Authors:  Ali Soleimani; Alireza Moayyeri; Shahin Akhondzadeh; Mohsen Sadatsafavi; Hamidreza Tavakoli Shalmani; Akbar Soltanzadeh
Journal:  BMC Neurol       Date:  2004-09-11       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.